Summary Document for Interim Clinical Considerations

for Use of COVID-19 Vaccines Currently Authorized in the United States

	Pfizer-BioNTech	Moderna	Janssen
Vaccine type	mRNA	mRNA	Replication-incompetent adenovirus type 26 vector
Authorized age groups	≥12 years	≥18 years	≥18 years
Dose	30 µg	100 µg	5×10^{10} viral particles
Dose volume	0.3 ml	0.5 ml	0.5 ml
Number of doses in series	2*	2*	1
Interval between doses	3 weeks (21 days)	1 month (28 days)	N/A
All currently authorized COVID-19 vaccines			
Interchangeability of vaccines	■ Vaccines are not interchangeable. However, in exceptional situations, such as a contraindication to a second dose of mRNA vaccine, interchangeability may be allowed.†		
Coadministration with other vaccines	■ COVID-19 vaccine and other vaccines may be administered on the same day, as well as any interval without respect to timing. When deciding whether to administer COVID-19 vaccine and other vaccines, providers should consider whether the patient is behind or at risk of becoming behind on recommended vaccines, their risk of vaccine-preventable diseases (e.g., during an outbreak), and the reactogenicity profile of the vaccines.		
Persons with prior or current COVID-19	■ COVID-19 vaccines can be given safely to people with prior SARS-CoV-2 infection ■ Defer vaccination until person has recovered from the acute illness and criteria have been met for them to discontinue isolation		
Women aged <50 years	■ Can receive any FDA-authorized vaccine but should be informed of risk of thrombosis with thrombocytopenia syndrome (TTS) after receipt of Janssen (Johnson & Johnson) COVID-19 Vaccine and the availability of other COVID-19 vaccine options		
Persons who received monoclonal antibodies or convalescent plasma for COVID-19 treatment	■ Defer vaccination for at least 90 days		
Persons with a known SARS-CoV-2 exposure	■ People in community or outpatient setting should defer vaccination until quarantine period has ended ■ Residents or patients in congregate settings may be vaccinated if they do not have symptoms consistent with COVID-19		
History of heparin-induced thrombocytopenia (HIT)	■ If within 90 days of illness, offer an mRNA vaccine, after 90 days vaccinate with any FDA-authorized COVID-19 vaccine		

Summary Document for Interim Clinical Considerations

for Use of COVID-19 Vaccines Currently Authorized in the United States

All currently authorized COVID-19 vaccines	
Persons with underlying conditions	■ May receive COVID-19 vaccine
Persons with moderate to severe immune compromise	■ Can receive any FDA-authorized COVID-19 vaccine • 1 dose Janssen COVID-19 Vaccine; currently no recommendation for an additional dose, or • 2-doses of an mRNA COVID-19 vaccine; consider an additional dose at least 28 days after completion of the primary 2-dose series
Persons with a history of Guillain-Barré Syndrome	■ Can receive any FDA-authorized COVID-19 vaccine, however, discuss the availability of mRNA vaccines to offer protection against COVID-19
Pregnant or breastfeeding people or people trying to get pregnant	■ Are recommended to receive a COVID-19 vaccine, inform of risk of TTS after receipt of Janssen (Johnson & Johnson) COVID-19 Vaccine and the availability of other options
Adolescents	■ Adolescents aged 12-17 are ONLY eligible for Pfizer-BioNTech COVID-19 Vaccine ■ Adolescents aged 18 years and older are eligible for all COVID-19 vaccines
Persons vaccinated outside the United States	■ Received all recommended doses of an FDA-authorized COVID-19 vaccine, do not need additional doses ■ Received a non FDA-authorized vaccine • If vaccine is listed for emergency use by the World Health Organization (WHO) and received all recommended doses, do not need any additional doses with an FDA-authorized vaccine • If vaccine is listed for emergency use by WHO, but has not received all recommended doses, may be offered a complete FDA-authorized series • If vaccine is not listed for emergency use by WHO, may be offered a complete FDA-authorized COVID-19 vaccine series
Contraindications	■ Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to component of the COVID-19 vaccine ■ Immediate (within 4 hours of exposure) allergic reaction of any severity to a previous dose or known (diagnosed) allergy to a component of the vaccine
Precaution	■ Immediate allergic reaction to any other vaccine or injectable therapy (i.e., intramuscular, intravenous, or subcutaneous vaccines or therapies [excluding subcutaneous immunotherapy for allergies, i.e., "allergy shots"])
Post-vaccination observation periods	■ **30 minutes:** persons with a precaution to vaccination (i.e., history of an immediate allergic reaction of any severity to a vaccine or injectable therapy) and persons with a history of anaphylaxis due to any cause ■ **15 minutes:** all other persons
SARS-CoV-2 antibody testing	■ Antibody testing not recommended for vaccine decision-making or to assess immunity following vaccination

*Consider an additional dose at least 28 days after the initial 2-dose primary series for people with moderate to severe immune compromise.

†Although CDC provides considerations for a mixed series in exceptional circumstances, this is still considered an administration error that requires VAERS reporting